

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Attorney Docket No.: 0512-1277	Application No.: 10/533,443
	Applicant: Jose COURTY et al.	
	Filing Date: November 21, 2005	Group Art Unit: 1664

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing date (if appropriate)
	6,932,973	08/23/2005	BARRITAUULT et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	2 799 465	04/13/2001	FRANCE			*	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Isabelle BERNARD-PIERROT et al., "The Lysine-rich C-terminal Tail of Heparin Affin Regulatory Peptide is Required for Mitogenic and Tumor Formation Activities", Journal of Biological Chemistry, Vol. 276, No. 15, April 13, 2001, pp. 12228-12234
	Anil K. CHAUHAN et al., "Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice", Proc. Natl. Acad. Sci. USA, Vol. 90, January 1993, pp. 679-682
	Rangana CHOUDHURI et al., "An Angiogenic Role for the Neurokines Midkine and Pleiotrophin in Tumorigenesis", Cancer Research, Vol. 57, May 1, 1997, pp. 1814-1819
	Jose COURTY et al., "Mitogenic Properties of a New Endothelial Cell Growth Factor Related to Pleiotrophin", Biochemical and Biophysical Research Communications, Vol. 180, No. 1, October 15, 1991, pp. 145-151
	Wenjing FANG et al., "Pleiotrophin Stimulates Fibroblasts and Endothelial and Epithelial Cells and is Expressed in Human Cancer", Journal of Biological Chemistry, Vol. 267, No. 36, December 25, 1992, pp. 25889-25897
	Soichi KOJIMA et al., "Synthetic Peptides Derived from Midkine Enhance Plasminogen Activator Activity in Bovine Aortic Endothelial Cells", Biochemical and Biophysical Research Communications, Vol. 206, No. 2, January 17, 1995, pp. 468-473
	Soichi KOJIMA et al., "Midkine Enhances Fibrinolytic Activity of Bovine Endothelial Cells", Journal of Biological Chemistry, Vol. 270, No. 16, April 21, 1995, pp. 9590-9596
	P. E. MILHIET et al., "Upregulation of the angiogenic factor heparin affin regulatory peptide by progesterone in rat uterus", Journal of Endocrinology, Vol. 158, 1998, pp. 389-399
	Heikki RAUVALA, "An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors", EMBO Journal, Vol. 8, No. 10, 1989, pp. 2933-2941
	Gerald E. STOICA et al., "Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin", Journal of Biological Chemistry, Vol. 276, No. 20, May 18, 2001, pp. 16772-16779
	Francis VACHEROT et al., "Glycosaminoglycans Differentially Bind HARP and Modulate Its Biological Activity", Journal of Biological Chemistry, Vol. 274, No. 12, March 19, 1999, pp. 7741-7747
	Francis VACHEROT et al., "Involvement of Heparin Affin Regulatory Peptide in Human Prostate Cancer", The Prostate, Vol. 38, 1999, pp. 126-136
	Anton WELLSTEIN et al., "A Heparin-binding Growth Factor Secreted from Breast Cancer Cells Homologous to a Developmentally Regulated Cytokine", Journal of Biological Chemistry, Vol. 267, No. 4, February 5, 1992, pp. 2582-2587

EXAMINER:	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

* Abstract provided for the Examiner's convenience

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Attorney Docket No.: 0512-1277	Application No.: 10/533,443
	Applicant: Jose COURTY et al.	
	Filing Date: November 21, 2005	Group Art Unit: 1664
	Hsiu-Jeng YEH et al., "Upregulation of Pleiotrophin Gene Expression in Developing Microvasculature, Macrophages, and Astrocytes after Acute Ischemic Brain Injury", Journal of Neuroscience, Vol. 18, No. 10, May 15, 1998, pp. 3699-3707	

EXAMINER:	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

* Abstract provided for the Examiner's convenience